COMPASS Pathways (CMPS)
| Bid | 2.86 |
| Market Cap | 196.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -155.32M |
| EPS (ttm) | -2.3 |
| PE Ratio (ttm) | -1.24 |
| Forward PE | -2.03 |
| Analyst | Buy |
| Ask | 2.87 |
| Volume | 455,331 |
| Avg. Volume (20D) | 1,198,315 |
| Open | 2.90 |
| Previous Close | 2.94 |
| Day's Range | 2.72 - 2.90 |
| 52-Week Range | 2.72 - 10.31 |
| Beta | 2.29 |
About CMPS
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in Augu...
Analyst Forecast
According to 7 analyst ratings, the average rating for CMPS stock is "Buy." The 12-month stock price forecast is $16.5, which is an increase of 476.92% from the latest price.
Stock Forecasts
2 months ago · businesswire.com
Compass Pathways Appoints Steve Levine, M.D., as Chief Patient OfficerLONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental ...